These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29694790)

  • 1. The role of mass spectrometry in the characterization of biologic protein products.
    Rathore D; Faustino A; Schiel J; Pang E; Boyne M; Rogstad S
    Expert Rev Proteomics; 2018 May; 15(5):431-449. PubMed ID: 29694790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent applications of quantitative mass spectrometry in biopharmaceutical process development and manufacturing.
    Li X
    J Pharm Biomed Anal; 2023 Sep; 234():115581. PubMed ID: 37494866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass spectrometry for structural characterization of therapeutic antibodies.
    Zhang Z; Pan H; Chen X
    Mass Spectrom Rev; 2009; 28(1):147-76. PubMed ID: 18720354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid-phase separations coupled with ion mobility-mass spectrometry for next-generation biopharmaceutical analysis.
    Makey DM; Ruotolo BT
    Expert Rev Proteomics; 2024; 21(5-6):259-270. PubMed ID: 38934922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals.
    Srebalus Barnes CA; Lim A
    Mass Spectrom Rev; 2007; 26(3):370-88. PubMed ID: 17410555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein mass spectrometry: applications to analytical biotechnology.
    Nguyen DN; Becker GW; Riggin RM
    J Chromatogr A; 1995 Jun; 705(1):21-45. PubMed ID: 7620570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biopharmaceutical quality control with mass spectrometry.
    Liu S; Schulz BL
    Bioanalysis; 2021 Aug; 13(16):1275-1291. PubMed ID: 34463131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeutics.
    Kaltashov IA; Bobst CE; Abzalimov RR; Wang G; Baykal B; Wang S
    Biotechnol Adv; 2012; 30(1):210-22. PubMed ID: 21619926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
    Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
    MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sweet spot for biologics: recent advances in characterization of biotherapeutic glycoproteins.
    O'Flaherty R; Trbojević-Akmačić I; Greville G; Rudd PM; Lauc G
    Expert Rev Proteomics; 2018 Jan; 15(1):13-29. PubMed ID: 29130774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of protein therapeutics by mass spectrometry: recent developments and future directions.
    Chen G; Warrack BM; Goodenough AK; Wei H; Wang-Iverson DB; Tymiak AA
    Drug Discov Today; 2011 Jan; 16(1-2):58-64. PubMed ID: 21093608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphoproteomics by mass spectrometry and classical protein chemistry approaches.
    Salih E
    Mass Spectrom Rev; 2005; 24(6):828-46. PubMed ID: 15538747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in structural mass spectrometry methods in the context of biosimilarity assessment: from sequence heterogeneities to higher order structures.
    Castel J; Delaux S; Hernandez-Alba O; Cianférani S
    J Pharm Biomed Anal; 2023 Nov; 236():115696. PubMed ID: 37713983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scientific Best Practices for Primary Sequence Confirmation and Sequence Variant Analysis in the Development of Therapeutic Proteins.
    Lund A; Ren D; Rogers RS; Rouse JC; Yu XC; Valliere-Douglass JF
    J Pharm Sci; 2021 Feb; 110(2):619-626. PubMed ID: 33212163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Retrospective Evaluation of the Use of Mass Spectrometry in FDA Biologics License Applications.
    Rogstad S; Faustino A; Ruth A; Keire D; Boyne M; Park J
    J Am Soc Mass Spectrom; 2017 May; 28(5):786-794. PubMed ID: 27873217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Qualitative and quantitative characterization of protein biotherapeutics with liquid chromatography mass spectrometry.
    Qu M; An B; Shen S; Zhang M; Shen X; Duan X; Balthasar JP; Qu J
    Mass Spectrom Rev; 2017 Nov; 36(6):734-754. PubMed ID: 27097288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intact mass analysis of monoclonal antibodies by capillary electrophoresis-Mass spectrometry.
    Han M; Rock BM; Pearson JT; Rock DA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Feb; 1011():24-32. PubMed ID: 26751590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of molecular targets of natural products by mass spectrometry.
    Cheng KW; Wong CC; Wang M; He QY; Chen F
    Mass Spectrom Rev; 2010; 29(1):126-55. PubMed ID: 19319922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced mass spectrometry-based methods for the analysis of conformational integrity of biopharmaceutical products.
    Bobst CE; Kaltashov IA
    Curr Pharm Biotechnol; 2011 Oct; 12(10):1517-29. PubMed ID: 21542797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass spectrometry-based methods in characterization of the higher order structure of protein therapeutics.
    Kaltashov IA; Bobst CE; Pawlowski J; Wang G
    J Pharm Biomed Anal; 2020 May; 184():113169. PubMed ID: 32092629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.